scholarly journals Kambô-Induced Systemic Inflammatory Response: A Case Report of Acute Disease Progression of Cholangiocarcinoma

2021 ◽  
Vol 20 ◽  
pp. 153473542199910
Author(s):  
Shira Peleg Hasson ◽  
Eliya Shachar ◽  
Rivka Kessner ◽  
Shulim Shpigel ◽  
Ido Wolf

Kambô is a cleansing ritual involving the application of a toxin produced by the giant leaf frog ( Phyllomedusa bicolor). The Kambô ritual has increasingly been adopted among cancer patients in Europe. Accumulating data indicate various adverse effects. We report another severe adverse reaction to Kambô, a systemic inflammatory response syndrome mimicking disease progression in a patient with cholangiocarcinoma. We describe a systemic reaction to Kambô, manifested as tachycardia, tachypnea, impaired liver cholestatic enzymes, and enlargement of lymphadenopathy mimicking disease progression. The clinical features and onset of symptoms, the rapid reaction, and the lack of other identified causes make the diagnosis of Kambô-induced SIRS highly probable. This case report calls for future studies examining standard oncological care such as chemotherapy, radiotherapy, and immunotherapy in conjunction with alternative therapy. Additionally, greater awareness and physician education should be promoted, encouraging inquiry of oncology patients’ administration of alternative, complementary, and integrative medicine.


Author(s):  
Tarali Devi ◽  
Subhash Sarma ◽  
Urmi Choudhury

<p>Cerebroprotein hydrolysate is a newer pharmacological neurotropic agent and considered as a promising therapeutic agent for dementia, Alzheimer’s disease, traumatic brain injury and acute ischaemic stroke. Studies revealed that most of the side effects are minor. Here, we reported a case of Systemic inflammatory response syndrome (SIRS) probably due to use of Cerebroprotein hydrolysate in a patient with acute ischaemic stroke.</p>



2019 ◽  
Vol 40 (5) ◽  
pp. 723-724 ◽  
Author(s):  
Jake Laun ◽  
Katie Laun ◽  
Adeel Farooqi ◽  
David J Smith

Abstract Burn patients are often plagued by fever due to the inflammatory nature of their injuries as well as the normal postoperative systemic inflammatory response syndrome. One etiology for fever, often not initially considered, is drug-induced fever. A rare cause of drug-induced fever is heparin with only one documented case reported in the literature. We present a case of heparin-induced fever in a patient who experienced a 32% total BSA friction burn after a motorcycle crash.







Author(s):  
Andressa R O Lima ◽  
Cynthia C Cardoso ◽  
Priscilla R B Bentim ◽  
Carolina M Voloch ◽  
Átila D Rossi ◽  
...  

Abstract Vertical transmission of SARS-CoV-2 has already been described, while clinical consequences to the fetus are still under investigation. This article reports a case of systemic fetal inflammatory response and pericardial effusion. As far as is known, this is the first case of fetal/neonatal cardiac complications related to SARS-CoV-2 infection.



2017 ◽  
Vol 14 (4) ◽  
pp. 4906-4910
Author(s):  
Hongyun Wei ◽  
Waqas Choudhary ◽  
Rong He ◽  
Chunhui Ouyang ◽  
Zongyong Cheng ◽  
...  


2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3055-3055 ◽  
Author(s):  
Claire Gervais ◽  
Pascaline Boudou-Rouquette ◽  
Anne Jouinot ◽  
Olivier Huillard ◽  
Jerome Alexandre ◽  
...  

3055 Background: Nivolumab is the first checkpoint immunotherapeutic agent approved for NSCLC. By enabling host immune-mediated cytotoxic activity against tumor cells, nivolumab induces a tumor response in 15% of patients (pts). However, host-related parameters to predict nivolumab activity are still missing. We evaluated the predictive and prognostic value of the presence of a systemic inflammatory response. Methods: From July 2015 to December 2016, we measured at nivolumab initiation the Glasgow Prognostic Score (GPS), a cumulative prognostic score based on C-reactive protein and albumin, the neutrophil-lymphocyte ratio (NLR), the Nutrition Risk Index (NRI) and the Prognostic Nutritional Index (PNI). Univariate and multivariate analyses tested the association between initial patient characteristics and clinical outcome. Results: The characteristics of the 57 consecutive pts analyzed are: median age of 66 years (range 41-78), 65% non-squamous cell lung cancer, 61.4% males and 52.6% Performance Status (PS) 0-1. GPS was 0 in 27 (47.4%), 1 in 21 (36.8%) and 2 in 9 (15.8%) pts. In multivariate analysis, parameters associated with disease progression (per RECIST 1.1) were GPS (1-2 vs 0; HR 1.45 [1.11-1.90], p= 0.009) and number of metastatic sites (>2 vs ≤ 2; HR: 0.75 [0.57-0.98], p = 0.04). Overall survival was significantly worse for pts with PS 2-3 vs PS 0-1 (p=0.01) and for pts with GPS 2 vs GPS 0-1 (p=0.01). The GPS was an independent predictive marker of progression and was superior to other inflammation-based prognostic scores in our cohort (Table). Conclusions: The Glasgow Prognostic Score (GPS) allows identifying patients with disease progression and long survivors among metastatic NSCLC patients treated with nivolumab. [Table: see text]





Sign in / Sign up

Export Citation Format

Share Document